AlphaCrest Capital Management’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-21,826
Closed -$1.76M 687
2022
Q3
$1.76M Buy
21,826
+13,659
+167% +$1.23M 0.11% 279
2022
Q2
$733K Sell
8,167
-4,797
-37% -$486K 0.04% 806
2022
Q1
$1.44M Sell
12,964
-153,135
-92% -$16.2M 0.08% 381
2021
Q4
$17.2M Buy
166,099
+153,978
+1,270% +$17.8M 0.64% 7
2021
Q3
$1.52M Sell
12,121
-22,270
-65% -$2.88M 0.08% 419
2021
Q2
$4.27M Buy
34,391
+10,477
+44% +$1.32M 0.18% 140
2021
Q1
$2.83M Buy
23,914
+5,199
+28% +$609K 0.16% 154
2020
Q4
$2.19M Buy
18,715
+10,857
+138% +$1.2M 0.18% 126
2020
Q3
$817K Sell
7,858
-58,501
-88% -$5.88M 0.09% 336
2020
Q2
$6.08M Buy
66,359
+52,160
+367% +$5M 1.01% 2
2020
Q1
$1.28M Sell
14,199
-24,493
-63% -$2.61M 0.16% 183
2019
Q4
$4.39M Buy
38,692
+18,910
+96% +$2.08M 0.36% 28
2019
Q3
$2.15M Sell
19,782
-7,683
-28% -$802K 0.13% 208
2019
Q2
$2.67M Sell
27,465
-35,573
-56% -$3.25M 0.23% 91
2019
Q1
$5.74M Buy
63,038
+56,128
+812% +$5.02M 0.87% 5
2018
Q4
$629K Buy
+6,910
New +$646K 0.19% 167

Other funds holding MDT

AlphaCrest Capital Management's MDT Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Medtronic (MDT) in Q4 2022, closing a stake of 21,826 shares — an estimated $1.76M sold.

AlphaCrest Capital Management first reported a position in MDT in Q4 2018 and held it in 16 quarters. The position peaked at $17.2M in Q4 2021. 1,961 funds tracked by Wall St. Rank hold MDT as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Medtronic position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 21,826 Medtronic shares in Q4 2022, an estimated $1.76M.
  • AlphaCrest Capital Management first reported a position in Medtronic in Q4 2018 and held it in 16 quarters.
  • AlphaCrest Capital Management's Medtronic position peaked at $17.2M in Q4 2021.
  • 1,961 funds tracked by Wall St. Rank held Medtronic as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.